Catatonia responsive to corticosteroids in a patient with an SCN2A variant

Am J Med Genet C Semin Med Genet. 2024 Dec;196(4):e32101. doi: 10.1002/ajmg.c.32101. Epub 2024 Jul 26.

Abstract

Variants in SCN2A are a known risk factor for developing autism spectrum disorder (ASD). Catatonia is a complex neuropsychiatric syndrome, which occurs at a higher rate in individuals with ASD. Catatonia has also been associated with COVID-19 infection, though the majority of these cases are associated with increased serum inflammatory markers. We present a case of a 15-year-old female with ASD and corticosteroid responsive stuporous catatonia to explore the relationship between SCN2A variants, ASD, COVID-19 exposure, and treatment refractory catatonia. Despite a lack of significantly elevated serum or CSF inflammatory markers, this patient showed significant improvement following initiation of corticosteroid therapy. This case presents a novel approach to the work-up and treatment of catatonia in individuals with SCN2A variants independent of elevated inflammatory markers.

Keywords: COVID‐19; SCN2A; autism; catatonia; steroids.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones* / therapeutic use
  • Autism Spectrum Disorder* / drug therapy
  • Autism Spectrum Disorder* / genetics
  • COVID-19 / complications
  • COVID-19 / genetics
  • Catatonia* / drug therapy
  • Catatonia* / genetics
  • Female
  • Humans
  • NAV1.2 Voltage-Gated Sodium Channel* / genetics
  • SARS-CoV-2

Substances

  • NAV1.2 Voltage-Gated Sodium Channel
  • SCN2A protein, human
  • Adrenal Cortex Hormones